Geron Corp (GERN)

[Joda]

Nice

Trial of JAK Inhibitor Fedratinib For Blood Cancer Discontinued
This is a quote from Dr. Tefferi's mouth today. Read the last sentance carefully.
Dr. Tefferi: "The value and limitations of JAK inhibitors in myeloproliferative neoplasms are now clear; they are capable of alleviating symptoms and reducing spleen size in about a third of patients but this activity is not durable (average duration of response is one to two years) and the drugs have not shown convincing evidence of disease-modifying activity. It is unlikely that additional JAK inhibitors (e.g. momelotinib) are going to do any better in the latter regard but might provide a better toxicity profile in some (e.g. anemia) but not in other (e.g. peripheral neuropathy) regard. There continues to be unmet need for patients with myelofibrosis and other myeloproliferative neoplasms in terms of disease-modifying drugs and patients might be best served by participating in clinical trials with drugs that might be capable of achieving this important goal."

-----------------------------------------------------------------------------------------------

We have to remember that Dr. Tefferi was once working with the Jak Inhibitors and left that program because of it's limitations..Now the good Doctor is working with Imetelstat and once said something to the effect that,if he had Myelofibrosis,he would want Imetelstat..Who would know better than THE Doctor that was involved with both drugs first hand?

So,who should we listen to? Some of the naysayers that infest this message board or Dr Tefferi? Geron/J&J get closer to their goal of approval for Imetelstat with each passing day..Let the professionals do their work

-------------------------------------------------------------------------------------------

Full story at;
http://medicalresearch.com/cancer-_-oncology/trial-of-jak-inhibitor-fedratinib-for-blood-cancer-discontinued/15131/